About Recombia Biosciences

Recombia Biosciences is a metabolic engineering platform that leverages the infinite potential of microorganisms for producing commercial scale ingredients. Our powerful partnership with Lesaffre enables cutting-edge solutions for industrial biomanufacturing to better nourish and protect the planet.

Company Timeline

Founded in 2019 from the innovative minds of three Stanford University researchers, Recombia Biosciences centered its core technology around multiplexed genome editing in yeast. Fueled by a strategic joint venture with industry giant Lesaffre International, Recombia opened its first labs in the heart of Silicon Valley's biotech hub.

2020

In 2020, upon the rapid achievement of several technical milestones, Recombia Biosciences was acquired by Lesaffre Group. As a subsidiary of Lesaffre Group, Recombia’s cutting edge metabolic engineering capabilities are an essential pillar to Lesaffre’s global R&D ecosystem.

2021

In 2021, Recombia opened their first labs in San Francisco.

2022

In 2022, Recombia expanded their footprint to Greater Boston through the acquisition of an innovative natural product discovery pipeline from Double Rainbow Bio.

2023

After the successful launch of their first product in 2023, Recombia Biosciences formally transferred their HQ to Boston positioning themselves at the epicenter of biotech innovation.

2024

As of September 2024, Recombia Biosciences has 150 employees and a robust discovery pipeline that serves metabolic engineering solutions to both internal and external partners in the biomanufacturing ecosystem.